Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of lifitegrast ophthalmic solution in Chinese patients with dry eye disease
CTR20253500Phase 3Terminated
- Sponsor
- Zhejiang Shapuaisi Pharmaceutical
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lifitegrast in dry eye syndrome (DED), sponsored by Zhejiang Shapuaisi Pharmaceutical. Started Oct 2025; status: terminated.
02
Drugs
lifitegrast
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20253500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253500.